Acrivon Therapeutics, Inc. (ACRV) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Acrivon Therapeutics is a clinical-stage biotechnology company focused on oncology, utilizing its proprietary AP3 platform to develop precision medicines. The company is advancing two primary clinical assets: ACR-368 (prexasertib), a CHK1/CHK2 inhibitor in a registrational Phase 2 trial for endometrial cancer, and ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 studies. The company has no approved products and has not generated any revenue from drug sales.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(18,234) | $(22,441) | $(58,920) | $(57,725) |
| Operating Expenses | $19,687 | $25,140 | $63,998 | $64,245 |
| Research & Development | $13,648 | $18,864 | $45,244 | $45,362 |
| General & Administrative | $6,039 | $6,276 | $18,754 | $18,883 |
| Cash & Investments (Total) | $134,400 (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(255,896) (as of Sept 30, 2025) |
Note: The filing does not provide specific margin percentages as the company has no revenue. Interest income for the nine months ended September 30, 2025, was $5.2 million.
Material Changes vs. Prior Period
- Reduced Operating Loss: Net loss for Q3 2025 decreased by $4.2 million compared to Q3 2024, primarily driven by a $5.2 million reduction in operating expenses.
- R&D Spend Shift: Total R&D expenses decreased in Q3 2025 due to a $7.1 million reduction in ACR-368 costs (fewer milestones and prioritization of endometrial cancer). Conversely, ACR-2316 costs increased by $0.9 million as the Phase 1 trial progressed.
- Interest Income Decline: Interest income dropped from $2.7 million in Q3 2024 to $1.5 million in Q3 2025, reflecting lower yields or investment balances compared to the prior year.
- Cash Position: Total cash, cash equivalents, and investments decreased from $181.6 million (current assets) at year-end 2024 to $130.4 million (current assets) at Q3 2025, with total liquid assets reported at $134.4 million.
Guidance, Outlook, and Risks
- Clinical Progress:
- ACR-368: Reported positive data in endometrial cancer with a 35% confirmed overall response rate (ORR) and 80% tumor shrinkage in biomarker-positive patients. A new Phase 2 trial combining ACR-368 with ultra low-dose gemcitabine (ULDG) was initiated in July 2025 for biomarker-unselected patients.
- ACR-2316: Phase 1 trial showed significant drug target engagement and initial clinical activity, including a confirmed partial response at Dose Level 3. A clinical data update is anticipated in the second half of 2025.
- Liquidity Outlook: Management believes existing cash and investments of $134.4 million are sufficient to fund operations into the second quarter of 2027. No additional funding has been raised in the current period.
- Risks:
- Continued operating losses and need for substantial additional capital to achieve profitability.
- Uncertainty regarding clinical trial outcomes and regulatory approvals.
- Potential impact of government shutdowns on FDA review timelines.
- Reliance on third-party manufacturers and collaborators (e.g., Akoya for companion diagnostics).
Key Facts for Investor Verification
- Runway: Verify the $134.4 million cash position and the projection to fund operations through Q2 2027.
- ACR-368 Data: Confirm the 35% ORR and 80% tumor shrinkage rates in the Phase 2 endometrial cancer trial and the status of the new combination trial with ULDG.
- ACR-2316 Progress: Monitor the upcoming clinical data update expected in H2 2025 and the determination of the recommended Phase 2 dose.
- Capital Needs: Assess the likelihood and timing of future equity or debt financing required to extend the runway beyond 2027.
- Contractual Obligations: Review the $168 million potential milestone payments to Lilly and $20.3 million to Akoya, noting that $18.2 million has already been paid to Akoya.